肝衰竭程度对拉米夫定治疗HBeAg阴性ACLF生存率的影响
【目的】探讨在HBeAg阴性慢加急性肝衰竭(ACLF)患者,拉米夫定治疗开始时肝功能衰竭程度对其转归的影响。【方法】分析71例接受拉米夫定+内科基础治疗患者在治疗开始时、治疗后或临终前的MELD值和血清HBV DNA载量,比较不同MELD值范围者生存率。【结果】MELD高分值组(≥31分)25例,治疗开始和临终前MELD值依次为33.97±3.59和38.89±9.29,HBV DNA载量分别为5.58±1.86和3.56±1.05 log10 copies/mL;MELD中分值组(23~31分)27例,MELD值由治疗前25.45±2.63升至治疗后29.65±9.90,HBV DNA载量由...
Saved in:
Format: | Article |
---|---|
Language: | zho |
Published: |
Editorial Office of Journal of Sun Yat-sen University
2012-01-01
|
Series: | Zhongshan Daxue xuebao. Yixue kexue ban |
Subjects: | |
Online Access: | http://xuebaoyx.sysu.edu.cn/zh/article/43575006/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
慢性乙肝患者拉米夫定耐药后出现肝功能衰竭的危险因素
by: 邓洪, et al.
Published: (2007-01-01) -
终末期肝病模型评分联合吲哚菁绿清除实验预测HBV相关慢加急性肝衰竭预后
by: 吴坤亮, et al.
Published: (2018-01-01) -
血小板聚集功能与慢性肝病病情程度的关系初探
Published: (2008-01-01) -
Effect of HBeAg/anti-HBe coexistence on HBeAg seroconversion in treatment-naïve chronic hepatitis B patients with peginterferon-α
by: Kaimin Song, et al.
Published: (2025-02-01) -
三阴性乳腺癌化疗后骨髓抑制与其预后的相关性分析
by: 夏坤健, et al.
Published: (2024-05-01)